Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Ceases Oral Copaxone Development

This article was originally published in The Pink Sheet Daily

Executive Summary

The company said it is still considering development of “various non-parenteral formulations” for the MS therapy.

You may also be interested in...



Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS

Compound fails to meet primary and secondary trial endpoints.

Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS

Compound fails to meet primary and secondary trial endpoints.

Teva/Active Biotech Initiate Phase III Program For Laquinimod Oral MS Therapy

Firm enters Phase III along with Acorda, Biogen Idec, others in race to bring first oral MS agent to market.

Related Content

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel